Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase IIIB, Multicenter, Open-label, PCI-32765 Ibrutinib Long-term Extension Study
Study Type: Treatment
Phase: III
NCTID: NCT01804686
Principal Investigator:
Marc Hoffmann
A Phase I/II Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma CLL/SLL or Non-Hodgkin Lymphoma NHL
Study Type: Treatment
Phase: I/II
NCTID: NCT03740529
Principal Investigator:
Marc Hoffmann
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma CLL/SLL: EVOLVE CLL/SLL Study
Study Type: Treatment
Phase: III
NCTID: NCT04269902
Principal Investigator:
Marc Hoffmann
A Randomized Phase II Study of Home Care Following Autologous Hematopoietic Stem Cell Transplantation
Study Type: Supportive Care
Phase: II
NCTID: NCT03667599
Principal Investigator:
Anthony Sung
A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab TG-1101 in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Study Type: Treatment
Phase: II
NCTID: NCT02656303
Principal Investigator:
Marc Hoffmann
Long-Term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated with Gene-Modified Cells
Study Type: Treatment
Phase: IV
NCTID: NCT05041309
Principal Investigator:
Nausheen Ahmed
A Pilot Trial of Atorvastatin in p53-Mutant and p53 Wild-Type Malignancies
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT03560882
Principal Investigator:
Joaquina Baranda
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease
A Phase III, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Na�ve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Study Type: Treatment
Phase: III
NCTID: NCT06479135
Principal Investigator:
Abdulraheem Yacoub